Immunogen | IMGN - Koszty Sprzedaży I Administracji



Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.84B 205M 2026-09
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Amgen USD 1.68B 40M 2026-09
Astellas Pharma JPY 215.29B 225M 2026-09
AstraZeneca USD 4.07B 1.73B 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Exelixis USD 154.56M 6.93M 2026-09
Halozyme Therapeutics USD 57M 10.71M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Intrexon USD 10.31M 41K 2024-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
MacroGenics USD 7.9M 1.81M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Novartis USD 3.08B 58M 2026-09
Pfizer USD 3.28B 132M 2026-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 140M 2026-06